CDK4/6 inhibitors plus RANKL inhibitors in syngeneic TNBC model

CDK4/6i alone have proven to be largely ineffective in breast cancer, even in the presence of functional retinoblastoma protein (pRB). In this study, we investigated the role of the RANK pathway in the response to CDK4/6i in pRB-proficient TNBC. Transcriptomic analysis of allografts revealed that combining CDK4/6i with RANKLi more effectively mounts an anti-tumoral immune response. Overall design: The transcriptomic profiles of tumor tissue from 4T1 xenografts implanted in NSG mice, collected after 12 days of treatment with Vehicle, OPG-Fc, Palbociclib or Palbociclib+OPG-Fc, were analyzed by RNASeq. 2-3 tumors per group were included.